PranAmritam

Science & pipeline

Training the immune system to find and destroy cancer

Therapeutic cancer vaccines teach a patient's own immune system to recognise tumour cells and destroy them. We develop five complementary non-mRNA platforms, from target discovery through to GMP lot release.

Platforms

A diversified, de-risked pipeline

  • 01

    Personalised peptide

    Lead platform
  • 02

    Dendritic cell

    Approval precedent
  • 03

    Recombinant protein / VLP

    Core pipeline
  • 04

    Viral vector

    Core pipeline
  • 05

    DNA & tumour lysate

    Exploratory
Scientist pipetting samples in an immuno-oncology research laboratory

Division 01

Cancer Research

  • Tumour antigen and neoantigen discovery from patient tumour/normal sequencing data
  • Shared tumour-associated antigens (MUC1, HER2, WT1, NY-ESO-1, GP100) for off-the-shelf vaccines
  • Immune profiling of the tumour microenvironment and biomarker discovery
  • AI-driven antigen prediction with HLA typing for vaccines adapted to Indian populations
  • Collaborations with cancer hospitals and research institutions
Visualisation of dendritic cells and T cells engaging a tumour cell

Division 02

Vaccine Design

  • Lead platform: personalised multi-epitope peptide vaccines with immune-stimulating adjuvants
  • Dendritic-cell vaccines, the only cancer vaccine class with an approval precedent
  • Recombinant protein, subunit and virus-like particle (VLP) vaccines
  • Replication-deficient viral vectors (adenovirus, poxvirus)
  • Exploratory DNA and tumour-lysate vaccines for checkpoint-inhibitor combinations
GMP cleanroom manufacturing suite with technicians in cleanroom gowns

Division 03

GMP Manufacturing

  • Grade B/C/D cleanroom suites for peptide synthesis and recombinant protein processing
  • Closed-system cell-processing suites for dendritic-cell vaccine preparation
  • Aseptic fill-finish and in-house QC laboratories
  • Patient-specific or batch-based delivery within clinically relevant timelines
  • CDSCO-compliant quality systems, built towards WHO-GMP for export

Why integration matters

From tumour biology to the bedside, without hand-off delays

One organisation that owns research, design and manufacture moves faster and protects its IP. It lowers cost per patient, times lot release to each patient's treatment schedule, and feeds clinical results straight back into vaccine design.

Raising up to US$100M

Help build affordable cancer immunotherapy in India

Qualified investors can request the investor deck, financial model and data-room access.

Request investor deck